Mechanism-Focused Research to Promote Adherence to Healthful Behaviors to Prevent Mild Cognitive Impairment (MCI) and Alzheimers Disease (AD) and AD-Related Dementias (ADRD) (R61/R33 Clinical Trial Required)

The summary for the Mechanism-Focused Research to Promote Adherence to Healthful Behaviors to Prevent Mild Cognitive Impairment (MCI) and Alzheimers Disease (AD) and AD-Related Dementias (ADRD) (R61/R33 Clinical Trial Required) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Mechanism-Focused Research to Promote Adherence to Healthful Behaviors to Prevent Mild Cognitive Impairment (MCI) and Alzheimers Disease (AD) and AD-Related Dementias (ADRD) (R61/R33 Clinical Trial Required): This Funding Opportunity Announcement (FOA) invites applications to address psychological and interpersonal mechanisms driving adherence to behaviors or lifestyle changes relevant to prevention of cognitive decline, Mild Cognitive Impairment (MCI), and Alzheimer's disease (AD) and AD-related dementias (ADRD). Mechanisms of adherence may be studied in new, early- to late-stage (including Stage I-IV) behavior change trials. Applications will seek to identify malleable, mechanistic, psychological, or interpersonal targets that, if modified, will strengthen adherence to, maintenance of, and continued/renewed engagement in behaviors that may promote cognitive health and prevent AD/ADRD. This FOA utilizes the R61/R33 Exploratory/Developmental Phased Award activity code. The R61 phase will support pilot research to identify, measure, and assess the malleability of psychological or interpersonal adherence-relevant targets that, if successful, can transition to the R33 phase. The R33 phase will utilize results from the R61 phase to implement rigorous, proof-of-concept intervention studies. The transition from the R61 to the R33 phase will be administratively reviewed for, and be dependent upon, successful completion of the go/no-go criteria specified for the R61 phase.

Federal Grant Title:	Mechanism-Focused Research to Promote Adherence to Healthful Behaviors to Prevent Mild Cognitive Impairment (MCI) and Alzheimers Disease (AD) and AD-Related Dementias (ADRD) (R61/R33 Clinical Trial Required)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-AG-23-034
Type of Funding:	Grant
CFDA Numbers:	93.866
CFDA Descriptions:	Information not provided
Current Application Deadline:	January 20th, 2023
Original Application Deadline:	January 20th, 2023
Posted Date:	October 3rd, 2022
Creation Date:	October 3rd, 2022
Archive Date:	February 25th, 2023
Total Program Funding:
Maximum Federal Grant Award:	$500,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	October 3rd, 2022

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement: https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-23-034.html
Grant Announcement Contact: NIH Grants Information
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Similar Government Grants: • Nathan Shock Centers Coordinating Center (U24 Clinical Trial Not Allowed); • Nathan Shock Centers of Excellence in Basic Biology of Aging (P30 Clinical Trial Not Allow...; • Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (...; • Exploring Proteogenomic Approaches to Unravel the Mechanisms of Mis-Folded Protein Accumul...; • Research Training in Aging for Medical Students (T35); • Technological Enhancements and Archiving for Surveys of the Elderly: SBIR (R43/44) Initiat...; • Technological Enhancements and Archiving for Surveys of the Elderly: STTR (R41/42) Initiat...; • Technology and Aging: NIA Small Business Technology Transfer Program Initiative (STTR [R41...
More Grants from the National Institutes of Health: • Hazardous Materials Worker Health and Safety Training (U45 Clinical Trials Not Allowed); • Lasker Clinical Research Scholars Program (Si2/R00 Clinical Trial Optional); • Type 1 Diabetes TrialNet Clinical Network Hub (U01 Clinical Trial Not Allowed); • Advancing HIV service delivery through pharmacies and pharmacists (R21 Clinical Trial Opti...; • Advancing HIV service delivery through pharmacies and pharmacists (R01 Clinical Trial Opti...